Abstract
Sex differences in the humoral immune responses to the seasonal quadrivalent influenza vaccine (QIV) in young adults (YA; 18-49yo) or high dose QIV in old adults (OA; 75+yo) were analyzed to evaluate how age-related changes in steroids impact sex differences in B cell responses.
Among YAs, females had greater H3N2, but not H1N1, neutralizing antibody titers and greater proportions of hemagglutinin (HA)+CD19+ B cells and HA+ memory B cells than males through 28 days post-vaccination (DPV), which was not observed among OAs. Machine learning algorithms illustrated that baseline (0 DPV) steroids, including 17-hydroxyprogesterone, estrogens, and testosterone, as well as HA+CD19+ B cells and HA+ antibody-secreting B cells (ASCs) were major predictors of subsequent seroconversion at 28 DPV, particularly in YA. Single cell RNA sequencing demonstrated CD19+ B cells from YA females had greater transcriptional activity at 7 DPV than YA males, with upregulation of genes with estrogen-response elements (EREs) along NF-κB-mediated TNF signaling pathways in B cell subsets, including naïve, memory, and ASCs, which was mitigated in OA. Estradiol treatment of ASCs from YA females, but not males, increased the number and size of HA+IgG+ ASCs and expression of genes with EREs along the NF-κB-mediated TNF signaling pathway, which were inhibited by an estrogen receptor antagonist. Pharmacological inhibition of either NF-κB or TNF signaling blocked the ability of E2 to upregulate antibody secretion from YA female ASCs. This study provides mechanistic insights into estrogen mediated increases in influenza vaccine-induced antibody responses among reproductive-aged females as compared with age-matched males and suggests a role for estrogen signaling in the reduction of sex differences in vaccine-induced immunity with old age.
One Sentence Summary Estrogenic activity in B cells causes greater influenza vaccine-induced immunity in young adult females than age-matched males, with these sex differences being mitigated in old adults.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding provided the National Institutes of Health NIA/ORWH Johns Hopkins Specialized Center of Research Excellence in sex differences (U54AG062333; SLK) and the NIAID Johns Hopkins Center of Excellence for Influenza Research and Response (75N93021C00045; AP and RR), with additional support from the Paul and Irma Milstein Foundation Program at the Johns Hopkins Center on Aging and Immune Remodeling (SXL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study involved two separate cohorts of human participants (young adults, 18-49 years old and old adults, 75+ years old), which were given ethical approval by the Johns Hopkins Institutional Review Boards (IRB00091667, NA_00092365).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Additional experiments were added, including evaluate changes in the expression of genes with estrogen response elements along the TNF signaling via NF-kB mediated pathway in the presence or absence of estradiol ex vivo. Additional experiments were added, including ex vivo analyses of estradiol-induced IgG secretion by antibody secreting cells in the presence or absence of NF-kB or TNF inhibitors.
Data Availability
All code can be accessed through GitHub at https://github.com/ayin0510/Influenza-Vaccine-Human-B-Cell-Project-2019-2020. The scRNA-seq transcriptomic data generated in this study have been deposited to the NIH GEO database (https://www.ncbi.nlm.nih.gov/geo/). All data are available in the main text or the supplementary materials.
https://github.com/ayin0510/Influenza-Vaccine-Human-B-Cell-Project-2019-2020
